High-Impact Form 4 Intelligence
Real-time SEC insider trading data with advanced filtering. Free beta.
Total Buys (Filtered)
$0
$0
Total Sells (Filtered)
$51.3M
$51,327,628
| Ticker | Company | Reporting Owner | Date | Value (USD) | Type | Form 4 |
|---|---|---|---|---|---|---|
|
ALNY
S
ALNYLAM PHARMACEUTICALS, INC.
Fitzgerald Kevin Joseph
• Officer • CSO & EVP, Head of Research
10b5-1 Sell
2026-03-05
$213,177x4
|
||||||
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
Officer • CSO & EVP, Head of Research
10b5-1 Sell
|
2026-03-05 | $213,177x4 | S | Form 4 |
|
ALNY
S
ALNYLAM PHARMACEUTICALS, INC.
Garg Pushkal
• Officer • EVP Chief R&D
10b5-1 Sell
2026-03-05
$778,812x4
|
||||||
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
Officer • EVP Chief R&D
10b5-1 Sell
|
2026-03-05 | $778,812x4 | S | Form 4 |
|
ALNY
S
ALNYLAM PHARMACEUTICALS, INC.
Fitzgerald Kevin Joseph
• Officer • CSO & EVP, Head of Research
Sell to Cover
2026-03-04
$204,508x8
|
||||||
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
Officer • CSO & EVP, Head of Research
Sell to Cover
|
2026-03-04 | $204,508x8 | S | Form 4 |
|
ALNY
S
ALNYLAM PHARMACEUTICALS, INC.
Garg Pushkal
• Officer • EVP Chief R&D
Sell to Cover
2026-03-04
$745,984x8
|
||||||
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
Officer • EVP Chief R&D
Sell to Cover
|
2026-03-04 | $745,984x8 | S | Form 4 |
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
CEO
Sell to Cover
|
2026-03-04 | $947,581x8 | S | Form 4 |
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
CFO
Sell to Cover
|
2026-03-04 | $797,351x8 | S | Form 4 |
|
ALNY
S
ALNYLAM PHARMACEUTICALS, INC.
Tanguler Tolga
• Officer • EVP, Chief Commercial Officer
Sell to Cover
2026-03-04
$745,984x8
|
||||||
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
Officer • EVP, Chief Commercial Officer
Sell to Cover
|
2026-03-04 | $745,984x8 | S | Form 4 |
|
ALNY
S
ALNYLAM PHARMACEUTICALS, INC.
Fitzgerald Kevin Joseph
• Officer • CSO & EVP, Head of Research
10b5-1 Sell
2026-03-03
$528,189x4
|
||||||
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
Officer • CSO & EVP, Head of Research
10b5-1 Sell
|
2026-03-03 | $528,189x4 | S | Form 4 |
|
ALNY
S
ALNYLAM PHARMACEUTICALS, INC.
Garg Pushkal
• Officer • EVP Chief R&D
10b5-1 Sell
2026-03-03
$567,546x4
|
||||||
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
Officer • EVP Chief R&D
10b5-1 Sell
|
2026-03-03 | $567,546x4 | S | Form 4 |
|
ALNY
S
ALNYLAM PHARMACEUTICALS, INC.
Fitzgerald Kevin Joseph
• Officer • CSO & EVP, Head of Research
Sell to Cover
2026-03-02
$523,584x10
|
||||||
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
Officer • CSO & EVP, Head of Research
Sell to Cover
|
2026-03-02 | $523,584x10 | S | Form 4 |
|
ALNY
S
ALNYLAM PHARMACEUTICALS, INC.
Garg Pushkal
• Officer • EVP Chief R&D
Sell to Cover
2026-03-02
$562,585x10
|
||||||
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
Officer • EVP Chief R&D
Sell to Cover
|
2026-03-02 | $562,585x10 | S | Form 4 |
|
ALNY
S
ALNYLAM PHARMACEUTICALS, INC.
Greenstreet Yvonne
• CEO
Sell to Cover
2026-03-02
$2,227,698Largex10
|
||||||
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
CEO
Sell to Cover
|
2026-03-02 | $2,227,698Largex10 | S | Form 4 |
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
CFO
Sell to Cover
|
2026-03-02 | $722,801x10 | S | Form 4 |
|
ALNY
S
ALNYLAM PHARMACEUTICALS, INC.
Tanguler Tolga
• Officer • EVP, Chief Commercial Officer
Sell to Cover
2026-03-02
$523,584x10
|
||||||
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
Officer • EVP, Chief Commercial Officer
Sell to Cover
|
2026-03-02 | $523,584x10 | S | Form 4 |
|
ALNY
S
ALNYLAM PHARMACEUTICALS, INC.
Garg Pushkal
• Officer • EVP Chief R&D
10b5-1 Sell
2026-02-27
$1,533,100Largex5
|
||||||
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
Officer • EVP Chief R&D
10b5-1 Sell
|
2026-02-27 | $1,533,100Largex5 | S | Form 4 |
|
ALNY
S
ALNYLAM PHARMACEUTICALS, INC.
Fitzgerald Kevin Joseph
• Officer • CSO & EVP, Head of Research
10b5-1 Sell
2026-02-17
$677,532
|
||||||
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
Officer • CSO & EVP, Head of Research
10b5-1 Sell
|
2026-02-17 | $677,532 | S | Form 4 |
|
ALNY
S
ALNYLAM PHARMACEUTICALS, INC.
Fitzgerald Kevin Joseph
• Officer • CSO & EVP, Head of Research
Sell to Cover
2026-02-13
$607,448
|
||||||
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
Officer • CSO & EVP, Head of Research
Sell to Cover
|
2026-02-13 | $607,448 | S | Form 4 |
|
ALNY
S
ALNYLAM PHARMACEUTICALS, INC.
Garg Pushkal
• Officer • EVP Chief R&D
Sell to Cover
2026-02-13
$695,201
|
||||||
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
Officer • EVP Chief R&D
Sell to Cover
|
2026-02-13 | $695,201 | S | Form 4 |
|
ALNY
S
ALNYLAM PHARMACEUTICALS, INC.
Greenstreet Yvonne
• CEO
Sell to Cover
2026-02-13
$2,157,542Large
|
||||||
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
CEO
Sell to Cover
|
2026-02-13 | $2,157,542Large | S | Form 4 |
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
CFO
Sell to Cover
|
2026-02-13 | $695,201 | S | Form 4 |
|
ALNY
S
ALNYLAM PHARMACEUTICALS, INC.
Tanguler Tolga
• Officer • EVP, Chief Commercial Officer
Sell to Cover
2026-02-13
$607,448
|
||||||
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
Officer • EVP, Chief Commercial Officer
Sell to Cover
|
2026-02-13 | $607,448 | S | Form 4 |
|
ALNY
S
ALNYLAM PHARMACEUTICALS, INC.
Fitzgerald Kevin Joseph
• Officer • CSO & EVP, Head of Research
10b5-1 Sell
2026-01-13
$848,065x6
|
||||||
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
Officer • CSO & EVP, Head of Research
10b5-1 Sell
|
2026-01-13 | $848,065x6 | S | Form 4 |
|
ALNY
S
ALNYLAM PHARMACEUTICALS, INC.
Fitzgerald Kevin Joseph
• Officer • CSO & EVP, Head of Research
Sell to Cover
2026-01-12
$547,927x21
|
||||||
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
Officer • CSO & EVP, Head of Research
Sell to Cover
|
2026-01-12 | $547,927x21 | S | Form 4 |
|
ALNY
S
ALNYLAM PHARMACEUTICALS, INC.
Garg Pushkal
• Officer • EVP Chief R&D
Sell to Cover
2026-01-12
$547,929x21
|
||||||
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
Officer • EVP Chief R&D
Sell to Cover
|
2026-01-12 | $547,929x21 | S | Form 4 |
|
ALNY
S
ALNYLAM PHARMACEUTICALS, INC.
Greenstreet Yvonne
• CEO
Sell to Cover
2026-01-12
$3,475,157Largex21
|
||||||
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
CEO
Sell to Cover
|
2026-01-12 | $3,475,157Largex21 | S | Form 4 |
|
ALNY
S
ALNYLAM PHARMACEUTICALS, INC.
Poulton Jeffrey V.
• CFO
Sell to Cover
2026-01-12
$1,008,766Largex21
|
||||||
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
CFO
Sell to Cover
|
2026-01-12 | $1,008,766Largex21 | S | Form 4 |
|
ALNY
S
ALNYLAM PHARMACEUTICALS, INC.
Tanguler Tolga
• Officer • EVP, Chief Commercial Officer
Sell to Cover
2026-01-12
$547,927x21
|
||||||
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
Officer • EVP, Chief Commercial Officer
Sell to Cover
|
2026-01-12 | $547,927x21 | S | Form 4 |
|
ALNY
M
ALNYLAM PHARMACEUTICALS, INC.
Greenstreet Yvonne
• CEO
Equity Compensation
2025-11-26
$499,756x8
|
||||||
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
CEO
Equity Compensation
|
2025-11-26 | $499,756x8 | M | Form 4 |
|
ALNY
M
ALNYLAM PHARMACEUTICALS, INC.
Fitzgerald Kevin Joseph
• Officer • CSO & EVP, Head of Research
Other
2025-11-17
$972,220
|
||||||
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
Officer • CSO & EVP, Head of Research
Other
|
2025-11-17 | $972,220 | M | Form 4 |
|
ALNY
S
ALNYLAM PHARMACEUTICALS, INC.
Fitzgerald Kevin Joseph
• Officer • CSO & EVP, Head of Research
10b5-1 Sell
2025-11-17
$5,483,990Whalex11
|
||||||
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
Officer • CSO & EVP, Head of Research
10b5-1 Sell
|
2025-11-17 | $5,483,990Whalex11 | S | Form 4 |
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
CEO
Other
|
2025-11-13 | $1,191,300Large | M | Form 4 |
|
ALNY
S
ALNYLAM PHARMACEUTICALS, INC.
Greenstreet Yvonne
• CEO
10b5-1 Sell
2025-11-13
$4,512,682Largex9
|
||||||
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
CEO
10b5-1 Sell
|
2025-11-13 | $4,512,682Largex9 | S | Form 4 |
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
CEO
Other
|
2025-11-12 | $1,814,393Largex2 | M | Form 4 |
|
ALNY
S
ALNYLAM PHARMACEUTICALS, INC.
Greenstreet Yvonne
• CEO
10b5-1 Sell
2025-11-12
$7,100,322Whalex11
|
||||||
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
CEO
10b5-1 Sell
|
2025-11-12 | $7,100,322Whalex11 | S | Form 4 |
|
ALNY
S
ALNYLAM PHARMACEUTICALS, INC.
Garg Pushkal
• Officer • EVP Chief R&D
10b5-1 Sell
2025-10-03
$1,364,387Largex5
|
||||||
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
Officer • EVP Chief R&D
10b5-1 Sell
|
2025-10-03 | $1,364,387Largex5 | S | Form 4 |
|
ALNY
S
ALNYLAM PHARMACEUTICALS, INC.
Fitzgerald Kevin Joseph
• Officer • CSO & EVP, Head of Research
Sell to Cover
2025-10-02
$1,103,451Largex12
|
||||||
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
Officer • CSO & EVP, Head of Research
Sell to Cover
|
2025-10-02 | $1,103,451Largex12 | S | Form 4 |
|
ALNY
S
ALNYLAM PHARMACEUTICALS, INC.
Garg Pushkal
• Officer • EVP Chief R&D
Sell to Cover
2025-10-02
$1,327,675Largex12
|
||||||
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
Officer • EVP Chief R&D
Sell to Cover
|
2025-10-02 | $1,327,675Largex12 | S | Form 4 |
|
ALNY
S
ALNYLAM PHARMACEUTICALS, INC.
Greenstreet Yvonne
• CEO
Sell to Cover
2025-10-02
$4,034,085Largex12
|
||||||
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
CEO
Sell to Cover
|
2025-10-02 | $4,034,085Largex12 | S | Form 4 |
|
ALNY
S
ALNYLAM PHARMACEUTICALS, INC.
Poulton Jeffrey V.
• CFO
Sell to Cover
2025-10-02
$1,727,284Largex12
|
||||||
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
CFO
Sell to Cover
|
2025-10-02 | $1,727,284Largex12 | S | Form 4 |
|
ALNY
S
ALNYLAM PHARMACEUTICALS, INC.
Tanguler Tolga
• Officer • EVP, Chief Commercial Officer
Sell to Cover
2025-10-02
$635,126x12
|
||||||
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
Officer • EVP, Chief Commercial Officer
Sell to Cover
|
2025-10-02 | $635,126x12 | S | Form 4 |